



#1/c TBing

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231.			
Typed or Printed Name	Kimberly W. Zuehlke		
Signature	<i>Kimberly W. Zuehlke</i>	Date	10/19/01

PRELIMINARY AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Attorney Docket Confirmation No.	SHIM006 8342	RECEIVED DEC 07 2001
	First Named Inventor	Takuya Tamatani et al.	
	Application Number	09/582,337	TECH CENTER 1600/2900
	Filing Date	September 18, 2000	
	Group Art Unit	1644	
	Examiner Name	P. Huynh	
	Title	Monoclonal Antibody Against Connective Tissue Growth Factor and Medicinal Uses Thereof	

Sir:

This is a Response to the Restriction Requirement dated June 19, 2001 and preliminary amendment to the patent application identified above. A Petition for a three (3) Month Extension of Time is submitted herewith, making this response timely filed on or before October 19, 2001. Prior to examination of the subject application, please enter the following amendments to the specification and claims:

AMENDMENTS

IN THE CLAIMS:

Please **cancel** claims 109-120, 122, 124-126 and 145-154 without prejudice or disclaimer. Please amend claims 104-108, 121, 123 and 127-144 and add new claim 155 as shown on the attached "Mark-Up Version of the Claims." A clean copy of the amended and added claims appear below.

104. (Once Amended) A non-human monoclonal antibody or a portion thereof, which is reactive to human, mouse and rat connective tissue growth factors (CTGFs).

105. (Once Amended) The non-human monoclonal antibody or a portion thereof according to claim 104, wherein said monoclonal antibody is produced by a hybridoma identified by international deposit accession No. ~~FERM BP-6208.~~

C